Therapeutics

#Business #Clinical trials #Therapeutics

Drug launches to drive NASH growth across major markets, says research

Several pharmacological treatments for non-alcoholic steatohepatitis (NASH) are expected to be launched in the seven major markets (7MM*) over the next 10 years. It is anticipated that these products can demand higher prices than the current off-label therapies, considering no therapy has been approved for the indication, and drive strong… Read More

#News #Trends & Analysis

#Cellular diagnostics #Therapeutics

Biofriendly protocells pump up blood vessels

An international team comprising researchers from the University of Bristol, and Hunan and Central South Universities in China, have prepared biocompatible protocells that generate nitric oxide gas – a known reagent for blood vessel dilation – that when placed inside blood vessels expand the biological tissue. In a new study… Read More

#News

#AI / data analytics / healthtech / informatics #Drug development #Drug discovery #Oncology #Therapeutics

Lantern Pharma AI milestone will cut cost, time and risk in developing new drug therapies

Lantern Pharma has reached a significant milestone by surpassing one billion curated data points on its RADR platform, a total it believes is the most amassed by any company in the biotech sector. The milestone, which was reached well ahead of schedule, enables new opportunities in Lantern’s work to identify and… Read More

#News

#AI / data analytics / healthtech / informatics #Clinical trials #Drug development #Therapeutics

First patient recruited for novel precision medicine trial for patients with hypertension

Closed Loop Medicine (CLM) a clinical stage therapeutics company developing drug and digital combination products, has recruited the first patient into its pivotal clinical trial investigating CLM’s integrated precision care solution for patients with hypertension. The clinical trial, called Personal COVID BP, will see up to 1,000 patients recruited for… Read More

#News

#Biotechnology #Oncology #Therapeutics

STORM Therapeutics uses Evotec platform to push oncology project towards clinical studies

STORM Therapeutics will use INDiGO, Evotec’s integrated, accelerated IND-enabling platform, to progress its STC-15 towards an IND application in 2021. STORM, a biotechnology company focused on the discovery and development of small molecule therapies modulating RNA epigenetics, has selected STC-15 as a first-in-class development candidate. STORM discovered STC-15, an orally… Read More

#Cancer Research #News

#Biopharmaceuticals #Oncology #Therapeutics

Merck’s acquisition of VelosBio will boost oncology push

Merck (known as MSD outside the United States and Canada), is paying  $2.75 billion for VelosBio, a clinical-stage biopharmaceutical company committed to developing first-in-class cancer therapies targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1). VelosBio’s lead investigational candidate is VLS-101, an antibody-drug conjugate (ADC) targeting ROR1 that is currently being… Read More

#Cancer Research #News

#Cell therapy #Therapeutics

Catalent to acquire Bone Therapeutics’ cell therapy facility for €12 million

Bone Therapeutics, the cell therapy company and Catalent Pharma Solutions, provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies have announced the signing of share purchase and supply agreements. The agreements will streamline and economise the manufacturing operations of ALLOB, Bone Therapeutics’ allogeneic… Read More

#News

#Antibodies #Covid-19 #Novel candidates #Therapeutics

Novel COVID-19 antibody therapy candidates identified by UK biotech consortium

The UK BIA Antibody Taskforce, a UK consortium developing antibodies for treating COVID-19 has reached a major milestone – the identification of differentiated antibody combinations that will be taken forward for further development as an antibody ‘cocktail’. The Taskforce developed an accelerated and rigorous multifaceted approach to create a pool… Read More

#Covid-19 #Editor's Choice #News #Trending News

#Assay development optimisation & technology #Covid-19 #Therapeutics

PerkinElmer immunoassay helps identify therapeutic compounds to tackle COVID-19

A research team at the National Center for Advancing Translational Sciences (NCATS), an arm of the National Institutes of Health (NIH), is working with PerkinElmer’s AlphaLISA immunoassay to help support the global search for effective COVID-19 therapeutics. The NCATS research project is focused on studying small molecule drug compounds that… Read More

#Covid-19 #News

#Covid-19 #Drug development #Therapeutics

Aerogen collaborates on development of COVID-19 inhaled therapies

Aerogen has released details of a collaborative effort to support global pharmaceutical companies developing COVID-19 vaccines and therapies. To date, more than ten million patients globally have been treated safely and effectively with Aerogen’s drug delivery technology. As the global scientific community rallies against the pandemic, there has been interest… Read More

#Covid-19 #News

#Antibodies #Biologics / Biotechnology #Therapeutics

Just-Evotec Biologics gets grant for antibody product for the prevention of COVID-19

Evotec’s Seattle-based subsidiary, Just–Evotec Biologics has received a grant from the Bill & Melinda Gates Foundation as part of the COVID-19 Therapeutics Accelerator to enable the development and production of monoclonal antibody (mAb) candidates for the prevention of severe COVID-19 in vulnerable populations in low and middle income countries. Under… Read More

#Covid-19 #News

#AI / data analytics / healthtech / informatics #Biopharma #Clinical trials #Covid-19 #Drug discovery #Therapeutics

Sitting down with…Biorelate

Daniel Jamieson is the CEO and Founder of Biorelate, a biomedical curation company that aims to accelerate insight and innovation in drug discovery. Lu Rahman spoke to him about his vision for the business, how COVID-19 has affected the landscape and the technology behind his drug discovery success. Biorelate was… Read More

#Opinion

#Covid-19 #Therapeutics

Exercise hormone may modulate genes linked with novel coronavirus

A study conducted by researchers at São Paulo State University (UNESP) suggests that irisin, a hormone secreted from muscles in response to exercise, could have a therapeutic effect on COVID-19 patients. When they analysed adipose cell gene expression, the researchers found that irisin modulated genes associated with replication of the… Read More

#Covid-19